BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer
Journal for ImmunoTherapy of Cancer · 2023-03 · 11 (3) · e005532
DOI: 10.1136/jitc-2022-005532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.03.2023. Verfasst von Chi Yin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Prostatic Neoplasms, Basic Helix-Loop-Helix Proteins. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, the Basic and Applied Basic Research Foundation of Guang-dong province.
Abstract (Originalsprache)
Background
The molecular characteristics of prostate cancer (PCa) cells and the immunosuppressive bone tumor microenvironment (TME) contribute to the limitations of immune checkpoint therapy (ICT). Identifying subgroups of patients with PCa for ICT remains a challenge. Herein, we report that basic helix-loop-helix family member e22 (BHLHE22) is upregulated in bone metastatic PCa and drives an immunosuppressive bone TME.
Methods
In this study, the function of BHLHE22 in PCa bone metastases was clarified. We performed immunohistochemical (IHC) staining of primary and bone metastatic PCa samples, and assessed the ability to promote bone metastasis in vivo and in vitro. Then, the role of BHLHE22 in bone TME was determined by immunofluorescence (IF), flow cytometry, and bioinformatic analyses. RNA sequencing, cytokine array, western blotting, IF, IHC, and flow cytometry were used to identify the key mediators. Subsequently, the role of BHLHE22 in gene regulation was confirmed using luciferase reporter, chromatin immunoprecipitation assay, DNA pulldown, co-immunoprecipitation, and animal experiments. Xenograft bone metastasis mouse models were used to assess whether the strategy of immunosuppressive neutrophils and monocytes neutralization by targeting protein arginine methyltransferase 5 (PRMT5)/colony stimulating factor 2 (CSF2) could improve the efficacy of ICT. Animals were randomly assigned to treatment or control groups. Moreover, we performed IHC and correlation analyses to identify whether BHLHE22 could act as a potential biomarker for ICT combination therapies in bone metastatic PCa.
Results
Tumorous BHLHE22 mediates the high expression of CSF2, resulting in the infiltration of immunosuppressive neutrophils and monocytes and a prolonged immunocompromised T-cell status. Mechanistically, BHLHE22 binds to the CSF2 promoter and recruits PRMT5, forming a transcriptional complex. PRMT5 epigenetically activates CSF2 expression. In a tumor-bearing mouse model, ICT resistance of Bhlhe22 + tumors could be overcome by inhibition of Csf2 and Prmt5.
Conclusions
These results reveal the immunosuppressive mechanism of tumorous BHLHE22 and provide a potential ICT combination therapy for patients with BHLHE22 + PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China.
- Orthopaedic Research Institute, Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, Guangdong, China.
- Department of Gastrointestinal Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China.
- Department of Pathology, the First People's Hospital of Guangzhou City, Guangzhou, Guangdong, China.
- Department of Orthopaedic Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China pengxsh@mail.sysu.edu.cn daiyh5@mail.sysu.edu.cn langchd@ustc.edu.cn.
ORCID-Profile: Xinsheng Peng
Förderung
- National Natural Science Foundation of China
- the Basic and Applied Basic Research Foundation of Guang-dong province
Zitieren
APA
Yin, C., Wang, M., Wang, Y., Lin, Q., Lin, K., Du, H., Lang, C., Dai, Y., & Peng, X. (2023). BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer. Journal for ImmunoTherapy of Cancer, 11(3), e005532. https://doi.org/10.1136/jitc-2022-005532
Vancouver
Yin C, Wang M, Wang Y, Lin Q, Lin K, Du H, et al. BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer. Journal for ImmunoTherapy of Cancer. 2023;11(3):e005532. doi:10.1136/jitc-2022-005532
BibTeX
@article{Yin2023,
author = {Yin, Chi and Wang, Min and Wang, Yingzhao and Lin, Qijun and Lin, Kaiyuan and Du, Hong and Lang, Chuandong and Dai, Yuhu and Peng, Xinsheng},
title = {BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {3},
pages = {e005532},
doi = {10.1136/jitc-2022-005532}
}
EUVIMED